STAT+: 7 challenges that could make or break Biogen’s 2022
Can Biogen pull itself back from the brink?
The company is ending 2021 with dismal sales of its treatment for Alzheimer’s disease and its stock depressed. Management is slashing the drug’s price and cutting expenses.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: 7 challenges that could make or break Biogen’s 2022 »
